Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.36 |
| ▸ | GLRB | P48167 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012908 | 0.85 | HTR6 (0.41) | HTR6DRD2KDM4EGAAALDH1A1 | |
| SCHEMBL1016146 | 0.81 | HTR6 (0.44) | HTR6DRD2KDM4EGAAALDH1A1 | |
| SCHEMBL1012906 | 0.75 | PDE4B (0.47) | HTR6DRD2KDM4EALDH1A1TP53 | |
| SCHEMBL1015179 | 0.73 | HTR6 (0.55) | HTR6 | |
| SCHEMBL30683332 | 0.72 | KDM1A (0.51) | DRD2ALDH1A1TP53DRD3MAPT | |
| SCHEMBL1014125 | 0.72 | HTR6 (0.47) | HTR6KDM4E | |
| SCHEMBL22342099 | 0.71 | PDE4B (0.39) | ALDH1A1GLRA3GLRBMAPT | |
| SCHEMBL1013369 | 0.69 | KMT2A (0.40) | HTR6KDM4EGAAALDH1A1DRD3 | |
| SCHEMBL1013368 | 0.67 | HTR6 (0.43) | HTR6KDM4EALDH1A1DRD3HRH3 | |
| SCHEMBL9320214 | 0.66 | NPY5R (0.58) | DRD2KDM4EALDH1A1MAPTHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | HTR6 1/4885DRD2 35/4885KDM4E 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.